Acadia Pharmaceuticals Inc (ACAD) Company Profile & Statistics

Acadia Pharmaceuticals Inc
ACAD
(Nasdaq - US)
Closed
16.20
-0.07 (-0.46%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
16.07
High
16.42
Low
15.66

About Acadia Pharmaceuticals Inc

CEO

Stephen R. Davis

Headquarters

12830 el camino real,suite 400

san diego, ca 92130, united states

Auditor

Ernst & Young LLP

Employees

598

Share Holders

Website

www.acadia pharm.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

Acadia Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	2.69B
Enterprise Value	2.54B
Enterprise Value/EBITDA (ttm)	21.84
Price to Earnings Ratio (ttm)	20.78
Price to Book (mrq)	4.67
Price to Sales (ttm)	2.90
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	91.51%
Operating Margin (ttm)	13.83%
Profit Margin (ttm)	13.69%
Return on Equity (ttm)	25.83%
Return on Invested Capital (ttm)	26.31%
Return on Assets (ttm)	14.71%

Income Statement

Revenue (ttm)	929.24M
Revenue Per Share (ttm)	5.58
Gross Profit (ttm)	851.31M
EBITDA (ttm)³	116.28M
Net Income Avi to Common (ttm)	128.51M
Diluted EPS (ttm)	0.78

Share Statistics

Beta (5Y Monthly)	0.38
52-Week Change	-29.34%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	166.39M
Dividend Yield	0.00%
Float ⁴	119.30M
% Held by Insiders	28.30%
% Held by Institutions	96.71%

Balance Sheet

Total Cash (mrq)	565.33M
Total Cash Per Share (mrq)	3.40
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	2.29%
Quick Ratio (mrq)	2.11%
Book Value Per Share (mrq)	3.47

Cash Flow

Operating Cash Flow Per Share (ytd)	0.71
Free Cash Flow (ytd)	117.27M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Acadia Pharmaceuticals Inc

Trade With A Regulated Broker